CD33 and inflammatory bowel disease: Meanwhile, we found that genetic HLA DR on plasmacytoid Dendritic Cell (OR: 0.85, 95% CI: 0.79–0.91, P=2.67 × 10−6), HLA DR on Dendritic Cell (OR: 0.84, 95% CI: 0.78–0.92, P=7.59 × 10−5) and HLA DR on CD33- HLA DR+ (OR: 0.84, 95% CI: 0.77–0.91, P=6.82 × 10−5) were elevated to reduce the risk of IBD (Table 2; Figure 2).